KR20150136588A - Ｅｇｆｒ의 발현을 침묵시키기 위한 ｄｎａ자임 - Google Patents

Ｅｇｆｒ의 발현을 침묵시키기 위한 ｄｎａ자임 Download PDF

Info

Publication number
KR20150136588A
KR20150136588A KR1020157022001A KR20157022001A KR20150136588A KR 20150136588 A KR20150136588 A KR 20150136588A KR 1020157022001 A KR1020157022001 A KR 1020157022001A KR 20157022001 A KR20157022001 A KR 20157022001A KR 20150136588 A KR20150136588 A KR 20150136588A
Authority
KR
South Korea
Prior art keywords
egfr
modified
oligonucleotide
sequence
mrna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020157022001A
Other languages
English (en)
Korean (ko)
Inventor
판-치르 양
웨이-윈 라이
코난 펙
Original Assignee
내셔널 타이완 유니버시티
아카데미아 시니카
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 내셔널 타이완 유니버시티, 아카데미아 시니카 filed Critical 내셔널 타이완 유니버시티
Publication of KR20150136588A publication Critical patent/KR20150136588A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/127—DNAzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Saccharide Compounds (AREA)
KR1020157022001A 2013-01-14 2014-01-14 Ｅｇｆｒ의 발현을 침묵시키기 위한 ｄｎａ자임 Ceased KR20150136588A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361752117P 2013-01-14 2013-01-14
US61/752,117 2013-01-14
PCT/US2014/011496 WO2014110577A1 (en) 2013-01-14 2014-01-14 Dnazyme for silencing the expression of egfr

Publications (1)

Publication Number Publication Date
KR20150136588A true KR20150136588A (ko) 2015-12-07

Family

ID=51167450

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157022001A Ceased KR20150136588A (ko) 2013-01-14 2014-01-14 Ｅｇｆｒ의 발현을 침묵시키기 위한 ｄｎａ자임

Country Status (7)

Country Link
US (1) US9856480B2 (enExample)
EP (1) EP2943578B1 (enExample)
JP (1) JP6574136B2 (enExample)
KR (1) KR20150136588A (enExample)
CN (1) CN105264084A (enExample)
CA (1) CA2898200A1 (enExample)
WO (1) WO2014110577A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220061311A1 (en) * 2018-11-05 2022-03-03 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for reducing cryopreservation toxicity
IL302594A (en) * 2020-11-09 2023-07-01 1E Therapeutics Ltd Catalytic sequence based methods of treating or preventing bacterial infections
CN116286831B (zh) * 2023-01-29 2024-02-20 珠海市人民医院 靶向egfr t790m突变体的核酸适配体及其在制备治疗肺癌药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040031072A1 (en) * 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
US7365185B2 (en) * 2000-07-19 2008-04-29 Monsanto Technology Llc Genomic plant sequences and uses thereof
AU3497701A (en) * 2000-02-08 2001-08-20 Ribozyme Pharmaceuticals, Inc. Nucleozymes with endonuclease activity
EP1767632A3 (en) * 2001-05-29 2009-12-30 Sirna Therpeutics, Inc. A method for local administration of synthetic double-stranded oligonucleotides targeting a VEGF receptor
US6890719B2 (en) * 2002-05-10 2005-05-10 The Board Of Trustess Of The University Of Illinois Fluorescence based biosensor
GB0224663D0 (en) * 2002-10-23 2002-12-04 Isis Innovation DNAzyme
WO2005108570A1 (ja) * 2004-05-11 2005-11-17 National University Corporation Yokohama National University 核酸酵素複合体
EP1766068A4 (en) * 2004-06-04 2010-03-03 Genentech Inc EGFR Mutations
BRPI0607235A2 (pt) * 2005-02-24 2009-08-25 Amgen Inc mutações do receptor do fator de crescimento epidérmico
CA2683559C (en) 2007-04-13 2019-09-24 Dana Farber Cancer Institute, Inc. Methods for treating cancer resistant to erbb therapeutics
CN103080314B (zh) * 2010-09-30 2016-04-13 Lsip基金运营联合公司 显性突变基因表达抑制剂

Also Published As

Publication number Publication date
EP2943578A4 (en) 2017-01-25
WO2014110577A8 (en) 2015-10-08
WO2014110577A1 (en) 2014-07-17
CA2898200A1 (en) 2014-07-17
EP2943578B1 (en) 2019-04-10
CN105264084A (zh) 2016-01-20
JP6574136B2 (ja) 2019-09-18
US9856480B2 (en) 2018-01-02
JP2016504046A (ja) 2016-02-12
US20160145625A1 (en) 2016-05-26
EP2943578A1 (en) 2015-11-18

Similar Documents

Publication Publication Date Title
EP4137509A1 (en) Combinations of mrnas encoding immune modulating polypeptides and uses thereof
JP2021074010A (ja) Ｔｍｐｒｓｓ６発現を調節するための化合物及び方法
KR20200044837A (ko) 안지오포이에틴-유사 3 (ANGPTL3)의 발현을 억제하기 위한 RNAi 작용제 및 조성물, 및 사용 방법
KR20200044013A (ko) 아포지단백질 C-III (APOC3)의 발현을 억제하기 위한 RNAi 작용제 및 조성물
AU2017268399A1 (en) Mrna combination therapy for the treatment of cancer
WO2015149056A1 (en) Inhibition of bruton's tyrosine kinase (btk) in the lung to treat severe lung inflammation and lung injury
AU2014229985B2 (en) Methods of treating colorectal cancer
EP3781689A1 (en) Synthetic rig-i-like receptor agonists
HK1206387A1 (en) Organic compositions to treat kras-related diseases
JP2025503034A (ja) 補体因子ｂを阻害するための組成物及び方法
WO2013016297A2 (en) Tumor selective chemokine modulation
US20130337048A1 (en) Method and compositions for treating hiv infection
EP2943578B1 (en) Dnazyme for silencing the expression of egfr
WO2020225309A1 (en) Fmrp and cancer treatment
WO2009042910A2 (en) Ship inhibition to direct hematopoietic stem cells and induce extramedullary hematopoiesis
US8008273B2 (en) SHIP-deficiency to increase megakaryocyte progenitor production
TWI580783B (zh) 用於靜默ｅｇｆｒ表現之去氧核糖核酸酶（ｄｎａｚｙｍｅ）
EP3936136A1 (en) Specific sirna molecules, composition and use thereof for the treatment of triple negative breast cancer
CN106795556A (zh) VGSC β3 蛋白质用于癌症预防、治疗及诊断检测的靶点
US20250120963A1 (en) Methods and compositions for the treatment of thrombocytopenia
WO2025178127A1 (ja) がんを処置するための医薬組成物
CA2940660A1 (en) Reduction of traf1 levels combined with nutrient stress for treating lymphocyte-related cancers
WO2011112554A1 (en) Novel therapeutic approaches for birt-hogg-dube (bhd) syndrome
HK40004825A (en) Combinations of mrnas encoding immune modulating polypeptides and uses thereof
HK40004825B (en) Combinations of mrnas encoding immune modulating polypeptides and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150813

Patent event code: PA01051R01D

Comment text: International Patent Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20151028

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190114

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20191213

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20200320

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20191213

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I